Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-05-31 00:00:00 ET · period of report 2022-05-30 · accession 0001725160-22-000116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-31 | 2022-05-30 | ZNTL | Gallagher Cam | Pres, Dir | A - Grant | $0.00 | +111.1K | 466.9K | +31% | $0 |
| D | 2022-05-31 | 2022-05-30 | ZNTL | Gallagher Cam | Pres, Dir | A - Grant | $0.00 | +333.2K | 333.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-30 | A | A | 111,072 | $0.00 | 466,885 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-05-30 | A | A | 333,218 | $0.00 | 333,218 | D | $24.75 · — to 2032-05-29 | 333,218 Common Stock | (F2) The options vest and become exercisable as to 25% of the total number of shares underlying the option on May 30, 2023 and as to the remaining 75% in 36 substantially equal monthly installments thereafter. |